Tag - IBI

Developments

Fresenius gets FDA breakthrough device designation for hemodialysis system

Fresenius Medical Care (NYSE:FMS) received FDA breakthrough device designation for its hemodialysis system, which is being developed for the prevention of blood clotting without the use of blood thinner medication. Many...

October 24, 2019

Executive Moves

Kelley Dealhoy joins Interface Biologics as VP of business development

Closely-held Interface Biologics (IBI) appointed Kelley Dealhoy to the position of VP business development.

December 4, 2018

Tag - IBI

Fresenius gets FDA breakthrough device designation for hemodialysis system

Kelley Dealhoy joins Interface Biologics as VP of business development

General

More